Suchergebnisse - "De Giorgi, Ugo"

PubPharm (105)

1

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype : A Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Lorusso, D. | Raspagliesi, F. | Ronzulli, D. | +20

2

AMEERA-4 : a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer

enthalten in: Breast cancer research : BCR | 2023

von Campone, M. | Bidard, F. | Neven, P. | +6

3

Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab

enthalten in: Clinical pharmacology and therapeutics | 2023

von Polano, M. | Bedon, L. | Dal Bo, M. | +19

4

Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer : Final Results From the Phase 2 METEORA-II Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Munzone, E. | Regan, M. | Cinieri, S. | +60

5

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2) : a randomised, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Agarwal, N. | Azad, A. | Carles, J. | +18

CommentIn: Lancet. 2023 Jul 22;402(10398):266-267. - PMID 37285866

6

INOVATYON/ ENGOT-ov5 study : Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

enthalten in: British journal of cancer | 2023

von Colombo, N. | Gadducci, A. | Sehouli, J. | +139

7

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3) : a multicentre, open-label, randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2023

von Pignata, S. | Scambia, G. | Schettino, C. | +128

CommentIn: Lancet Oncol. 2023 Mar;24(3):201-203. - PMID 37052963

8

Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes : A Post Hoc Analysis of the PROSPER Randomized Clinical Trial

enthalten in: The Journal of urology | 2023

von Hussain, M. | Sternberg, C. | Efstathiou, E. | +9

9

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR) : extended follow-up from the phase 3, randomised, open-label study

enthalten in: The Lancet. Oncology | 2023

von Choueiri, T. | Eto, M. | Motzer, R. | +25

ErratumIn: Lancet Oncol. 2023 Apr;24(4):e146. - PMID 36990611

10

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

enthalten in: The New England journal of medicine | 2023

von Fizazi, K. | Piulats, J. | Reaume, M. | +126

CommentIn: Nat Rev Urol. 2023 Apr;20(4):199. - PMID 36928618

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]